|
Detection of Somatic Variants in the KRAS Gene
|
|
General
|
| |
Clinical Use:
|
The presence of activating KRAS mutations is predictive of resistance to epidermal growth factor receptor (EGFR) inhibitor targeted therapy such as panitumumab (Vectibix®) and cetuximab (Erbitux®) in CRCs.
Approximately 30-50% of colorectal cancers (CRC) have an activating mutation (variant) in KRAS, more than 90% of KRAS mutations occur in codons 12 and 13 of exon 2 and rarer activating mutations occur in codons 61 and 59 of exon 3, and in codons 117 and 146 of exon 4.
The presence of KRAS variants is also used to assist in classification of pancreatic cysts.
The test is Medicare rebateable for metastatic colorectal cancer (stage IV) |
| |
Availability:
|
Samples are tested routinely during the testing laboratory's hours of operation.
Please contact testing laboratory for urgent requests. |
| |
Aliases/Synonyms:
| Kirsten Rat Sarcoma Viral Oncogene, |
| |
Code:
|
HST |
| |
Handling Instructions (to laboratory):
|
Contact testing laboratory for specific transport instructions. |
| |
Hyperlink:
|
|
| |
Reference Interval:
|
Not Applicable
|
Collection Requirements
|
| |
Container:
|
Sterile Container (STERILE), |
| |
Sample Type:
|
Fresh/Frozen Tissue; Formalin Fixed or FFPE Tissue; Cytological Fluid Samples; FNA |
| |
Minimum Collection Volume:
|
N/A |
| |
Collection Instructions:
|
Contact testing laboratory for specific collection instructions. |
Processing Requirements
|
| |
Alternate Containers:
|
|
| |
Processing Instructions:
|
|
| |
Minimum Assay Volume:
|
N/A |
| |
Stability:
|
Dependent on sample type |
| |
Transport Instructions (to testing laboratory):
|
Contact testing laboratory for specific transport instructions. |
Testing Locations
|
| |
Performed at:
|
|
Section
|
Department
|
Site
|
Contact Phone
|
| Molecular Pathology |
Anatomical Pathology |
QEII Medical Centre |
6457 2679 |
|
Last Updated : 06-11-2020 13:51 |